Neurocrine Biosciences Reports Disappointing Study Results
Neurocrine Biosciences experiences stock decline after two failed studies, remaining committed to finding new treatments for neurological disorders.
Neurocrine Biosciences experiences stock decline after two failed studies, remaining committed to finding new treatments for neurological disorders.
European stocks closed higher on Thursday, with gains across major indices. Top gainers include healthcare/life sciences company Orpea S.A. and invest...
AstraZeneca announces plans to enter the weight-loss drug market with its new product ECC5004. Despite being behind competitors, the company receives...
Syngenta delays IPO on Shanghai's main market due to market conditions. Q3 earnings and revenue decline. Syngenta announces executive reshuffle. Indus...
Unilever is sharing patents with the ice cream industry to create energy-efficient freezer cabinets worldwide and reduce greenhouse gas emissions.
Bond yields rise as traders anticipate comments from Fed Chair Jerome Powell, a job market update, and a U.S. government bond auction. Market drivers...
Israel's shekel has rebounded after the Hamas attack, supported by the central bank's liquidity injections. Positive trends include bond yield recover...
Sibanye-Stillwater acquires Reldan Metals Recycler for $211.5 million to expand their presence in the circular economy and pursue global expansion opp...
ArcelorMittal announces a decrease in Q3 earnings, with net profit and sales declining. The company attributes this to lower steel shipments and price...
AMC Entertainment Holdings reports a profit in Q3, exceeding expectations, despite challenges from potential future delays.